1,721,468 research outputs found
Observation of horizontal air showers with ARGO-YBJ
No full textA preliminary analysis of Extensive Air Showers reconstructed by ARGO-YBJ with zenith angle greater than 80° is reported. The measurement of the size spectrum and of the azimuthal distribution is discussed. A description of the topology of these events is also provided. © 2011 Elsevier B.V
Meta-analysis: High-dose statin pretreatment prevents periprocedural cardiac events in patients having PCI
No full textMeta-analysis: High-dose statin pretreatment prevents periprocedural cardiac events in patients having PCI
No full textDirectional coronary atherectomy: from therapeutic device to research tool in coronary artery disease
No full textDirectional coronary atherectomy (DCA) was introduced as a new percutaneous revascularization modality in 1990, and was initially applied to large vessels without tortuosity or calcification, with overall results including a 95% procedural success, 94% clinical success and 4.6% major complications (urgent bypass surgery in 3.8%, Q wave myocardial infarction in 1.7%, and hospital mortality in 0.3% of patients). In addition to its established efficacy for eccentric lesions, newer applications emerged such as treatment of saphenous vein grafts, thrombus-associated lesions, aorto-ostial lesions, failed or suboptional coronary angioplasty results, bifurcation lesions and use as a part of multi-vessel intervention. Comparative studies with coronary angioplasty such as CAVEAT I and II and CCAT showed better success rates with DCA vs coronary angioplasty, but failed to demonstrate benefit in restenosis rates. OARS and BOAT studies helped define optimal atherectomy techniques, which led to better acute angiographic results and to the "debulking plus stenting" concept. A spin-off of those clinical applications has been the opportunity to study the histology of tissue excised by DCA in vivo in different clinical settings. Such studies, investigating plaque ulceration, thrombosis and inflammation are reviewed, with special emphasis on new insights into unstable angina; the future of atherectomy research is also outlined with a categorization of various possible protocols to be applied utilizing coronary atherectomy specimens from live patients
Measurement of the cosmic rays light component (pHe) primary spectrum with ARGO-YBJ
No full textThe ARGO-YBJ experiment, located at the Yangbajing Cosmic Ray Laboratory (Tibet, 4300 m a.s.l., 606 g/cm 2) has an high segmentation that allows the detection of air showers with greater detail and lower energy threshold (a few hundred GeV) compared to other EAS arrays. The spectrum of the primary cosmic ray light (pHe) component in the energy range ∼10-100TeV is measured selecting quasi-vertical showers (θ<15°) with the reconstructed core position located in a 40×40 m 2 fiducial area. The results are compared with other measurements carried out with direct methods. © 2012 Elsevier B.V
Atorvastatin pretreatment in early percutaneous coronary intervention
No full textAccording to results of the Atorvastatin for Reduction of Myocardial Damage During Angioplasty-Acute Coronary Syndromes (ARMYDA-ACS) trial, short-term pretreatment with high-dose atorvastatin prior to percutaneous coronary intervention improves clinical outcome in subjects with unstable angina and non-ST-segment elevation myocardial infarction. These findings support the upstream administration of high-dose statins in subjects with acute coronary syndrome treated with an early invasive strategy
Contemporary issues on clopidogrel therapy
No full textIn this paper, data from available studies regarding some contemporary issues on clopidogrel therapy are analyzed. In particular, the following clinical questions have been considered and addressed: (a) Is early clopidogrel treatment needed in patients with acute coronary syndromes treated medically or undergoing percutaneous coronary intervention (PCI)? (b) What is the optimal clopidogrel loading dose in patients undergoing PCI? (c) Is pre-treatment with clopidogrel before PCI needed, or can clopidogrel loading be given in the catheter laboratory before intervention, but after coronary anatomy is known? (d) What is the optimal clopidogrel strategy in patients on chronic clopidogrel therapy undergoing PCI? (e) Does the degree of clopidogrel response influence clinical outcome in patients undergoing PCI?
Directional coronary atherectomy: from therapeutic device to research tool in coronary artery disease
No full textTransapical closure of paraprosthetic mitral leak in a patient with inferior vena cava interruption and azygos continuation
No full textPara-valvular leaks represent a relevant post-operative complication of cardiac valve replacement, often causing heart failure or severe hemolysis. We report a case of a 72 year-old woman with aortic and mitral mechanical prostheses who developed hemolytic anemia because of a para-prosthetic mitral leak. Chest tomography in such patient unexpectedly documented inferior vena cava interruption with azygos continuation into superior vena cava. Given the high surgical risk, the venous anomaly and the presence of the aortic valve prosthesis, transcatheter leak closure via antero-lateral mini-thoracotomy and transapical approach was performed
- …
